STD Testing for People on PrEP: How Medications Affect Accuracy and Recommended Testing Frequency

Key takeaways

• You can test for STIs while taking PrEP, and ongoing STI screening remains important.
• PrEP-related testing concerns primarily involve detecting HIV, not automatically making chlamydia, gonorrhea, or syphilis tests inaccurate.
• For oral PrEP, CDC guidance recommends HIV antigen/antibody and HIV-1 RNA testing at least every 3 months.
• Testing frequency for other STIs depends on symptoms, sexual practices, anatomy, exposure sites, and individual risk.
• Tell the clinician about every relevant exposure site so genital, rectal, or throat testing can be considered.

Yes. You can and should get STI testing while taking HIV pre-exposure prophylaxis, or PrEP. PrEP helps prevent HIV when used as prescribed, but it does not prevent chlamydia, gonorrhea, syphilis, or other non-HIV sexually transmitted infections. The main medication-related accuracy issue concerns HIV testing: antiretroviral medicines can suppress HIV replication and delay the appearance of markers that tests detect.

How PrEP can affect HIV test accuracy

HIV tests look for different evidence of infection, including antibodies, antigen, or viral RNA. CDC guidance explains that antiretroviral medicines used for PrEP or post-exposure prophylaxis can suppress viral load, delay seroconversion, and reduce the ability of some tests to detect infection. NIH guidance also notes that ongoing PrEP exposure can delay antigen and antibody detection during acute HIV infection.

Because of this possibility, PrEP monitoring uses more than a casual screening approach. For people taking oral PrEP, CDC recommends laboratory HIV antigen/antibody testing together with HIV-1 RNA testing at least every 3 months, along with assessment for signs or symptoms of acute HIV infection. Injectable cabotegravir PrEP has its own required follow-up intervals, during which CDC recommends antigen/antibody and HIV-1 RNA testing.

Why a home oral HIV test is not the preferred PrEP monitor

Oral rapid HIV self-tests can be useful in some settings, but CDC advises against relying on them for PrEP initiation or maintenance when better testing is available. They are less sensitive for recent infection, and recent antiretroviral exposure can further complicate interpretation. Laboratory-based blood testing is preferred for PrEP monitoring.

If an HIV result is reactive, discordant, indeterminate, or otherwise concerning, do not interpret it alone or change PrEP without clinical direction. A clinician can arrange repeat or supplemental testing and evaluate symptoms, recent exposures, medication use, and timing.

Does PrEP make chlamydia, gonorrhea, or syphilis tests inaccurate?

There is not sufficient evidence to say that standard PrEP medications generally invalidate chlamydia, gonorrhea, or syphilis tests. For these infections, accuracy is more closely related to factors such as when the exposure occurred, whether symptoms are present, which specimen was collected, the anatomic site exposed, and the characteristics of the test.

PrEP also does not protect against these infections. CDC recommends screening for chlamydia, gonorrhea, and syphilis before starting oral or injectable PrEP, with follow-up based on the person’s risk, sexual practices, anatomy, symptoms, and PrEP formulation.

Testing frequency while taking PrEP

There is no single STI schedule that fits everyone taking PrEP. HIV monitoring is tied to the PrEP formulation and clinical follow-up. Screening for other STIs is individualized. People with higher exposure risk may need testing more often, while symptoms or a recent concerning exposure may require prompt evaluation rather than waiting for a routine appointment.

Ask for testing at every relevant anatomic site

Urine testing alone does not check every possible exposure site. Depending on sexual practices and anatomy, testing may involve genital or urine specimens, rectal swabs, and throat or oropharyngeal swabs. Tell the clinician whether you have had receptive anal or oral exposure, genital exposure, or other contact that could affect which specimens are appropriate.

For chlamydia and gonorrhea, CDC emphasizes testing exposed sites and generally supports nucleic acid amplification tests, or NAATs, for relevant specimen types. Test performance can vary by assay and anatomic site. A targeted conversation about exposure is therefore an important part of accurate testing.

What about syphilis testing?

Syphilis screening is recommended for people at increased risk, including when clinical or sexual-history factors indicate it. The appropriate schedule is not automatically identical for every person on PrEP. A clinician can use risk, sexual practices, anatomy, symptoms, and clinical guidance when considering syphilis screening.

When to seek care instead of waiting

Arrange prompt clinical evaluation if you develop symptoms or have other concerns. Also seek advice after a recent high-risk HIV exposure or if you have an unclear HIV result.

Do not stop, restart, or change PrEP based only on an online article or an at-home result. The clinician managing your PrEP can select the appropriate HIV tests, determine whether additional STI testing is needed, and explain what follow-up means for your circumstances.

The bottom line

STI testing on PrEP is both possible and important. Separate HIV testing from testing for other STIs: PrEP can complicate HIV detection, which is why laboratory antigen/antibody and HIV-1 RNA testing are used for PrEP monitoring. It does not generally make chlamydia, gonorrhea, or syphilis tests inaccurate. For those infections, accurate screening depends on timing, symptoms, exposure sites, specimen type, and personal risk.